Scandiatransplant



Scandiatransplant Pediatric Heart and Lung Group (SPaedHLG) meeting Fall 2024

September 19th, 2024
Hurdalsjoen Hotel and Zoom at 17:00 – 19:00 Central European
<u>summertime</u> (GMT +2)

Meeting participants:

Klaus Juul (Copenhagen/Denmark) - National Key Contact Person 2023-2024 (Zoom) Michal Odermarsky (Lund/Sweden) - National Key Contact Person 2023-2024 (Zoom) Oscar Van Der Have (Lund, Sweden) (Zoom)

Tiina Ojala (Helsinki, Finland)

Thomas Möller (Oslo/Norway) - National Key Contact Person 2023-2024 (SPaedHLG chair 2024) (host of the meeting)

Taisto Sarkola (Helsinki/Finland)

Karin Tran-Lundmark (Lund/Sweden)

Håkan Wåhlander (Gothenburg/Sweden) National Key Contact Person 2023-2024

Aslak Kristoffersen (Oslo/Norway) (kept meeting minutes)

Maria Hurskainen (Helsinki, Finland)

Marie Bartos (Gothenburg/Sweden)

Katarina Övermo Tydén (Stockholm/Sweden)

Katharina Lannering (Gothenburg/Sweden)

Meeting minutes

- 1. Host of the meeting, Thomas Möller, welcomed everyone with a brief introduction.
- 2. All participants introduced themselves.
- 3. Registration of meeting participants as above.
- 4. The agenda for the meeting was approved.
- 5. The minutes from last meeting (9 April, 2024) was approved by the participants.
- 6. News or protocol updates since last meeting:
 - a. Gothenburg is currently working on the dd-cfDNA setup.

- b. Oslo has written protocols for cellular and antibody-mediated rejection.
- 7. SHLG and Scandiatransplant office information:
 - a. Ilse Duus-Weinreich (Scandiatransplant office) not present. Will join the spring meeting.
 - b. Updates on YASWA as a Nordic protocol and document sharing platform.
 - i. Guidelines not yet uploaded.
 - ii. Discussed if some can be uploaded to Scandiatransplant website (official) and some to Yaswa (restricted access)

8. CAV surveilance

- a. The group discussed regular CT vs photon CT and root angio versus selective coronar injection.
- 9. Long-term mechanical support
 - a. All centers now have a VAD-program including Berlin heart EXCOR, except Oslo. Oslo currently doing a mini-method evaluation of Berlin heart EXCOR.
 - b. Anticoagulation: The group discussed the use of Warfarin versus Bivalirudin. All centers except Helsinki use Warfarin. Will an oral anti-thrombin inhibitor (dabigatran) be an alternative in the future?

10. Organdonation in infants in Norway

a. Thomas is leading a national working group in Norway that recently presented their <u>report</u> on the needs and improvement opportunities regarding organ donation in children in general and infants in particular. The background for this is the lack of infant donors from Norway.

11. Research:

Report / update from studies within SPaedHLG region and other projects in progress

- a. MRI and CT coronaries in pediatric HTx follow-up (Ojala)
- b. Nordic Heart Transplant Study (Odermarsky / Van Der Have)
 - i. Oscar presented updated data. Stratified on three eras. 598 patients listed, 462 reached transplant. 14 listed for retransplant, 11 reached re-transplant. Most active centers Helsinki and Gothenburg. Presented listing outcomes (death ratio, transplant, withdrawal). Presented post-transplant survival numbers. Will get data on re-transplant from adult data. Will get data on the number of liver transplants among transplanted Fontan population.

- c. Swedish dd-cfDNA study. Is in manuscript. Will be submitted soon. Jens will defend his thesis on December 13th.
- d. Suggestions for new joint studies within SPaedHLG:
 - i. Mortality study of the cohort from the Nordic Heart Transplant Study.

12. Other:

a. The group discussed the age-criteria for heart patients on continuous inotropic support to qualify for the Priority 0 category in the Scandiatransplant thoracic exchange guidelines. The group will propose for the Scandiatransplant to raise the age limit from 16 to 18 years.

13.Next meeting:

- a. Spring 2025. Zoom meeting, preliminary Friday April 11, 15:00-17:00 CET
- b. Discuss if we should have shared meetings where we discuss transplant candidates.
- c. Finland will provide a summary from the national Fontan meeting.